Valneva announces positive phase 3 pivotal results for its single-shot chikungunya vaccine candidate

Saint herblain ( france), august 5 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced positive topline results from the phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, vla1553. vla1553 was recently awarded breakthrough designation status by the food and drug administration (fda).
VALN Ratings Summary
VALN Quant Ranking